[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA32551B1 - Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires - Google Patents

Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires

Info

Publication number
MA32551B1
MA32551B1 MA33602A MA33602A MA32551B1 MA 32551 B1 MA32551 B1 MA 32551B1 MA 33602 A MA33602 A MA 33602A MA 33602 A MA33602 A MA 33602A MA 32551 B1 MA32551 B1 MA 32551B1
Authority
MA
Morocco
Prior art keywords
degenerative
treatment
inflammatory diseases
compounds useful
new compounds
Prior art date
Application number
MA33602A
Other languages
Arabic (ar)
English (en)
Inventor
Christel Jeanne Marie Menet
Javier Blanc
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA32551B1 publication Critical patent/MA32551B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un nouveau composé [1,2,4]-triazolo-[1,5-a]-pyridine qui a la formule représentée par la formule (i). Ce composé peut être préparé sous forme de composition pharmaceutique, et peut être utilisé pour la prévention et le traitement d'une variété d'états chez des mammifères y compris des humains, comprenant, en tant qu'exemple non limitant, des maladies comprenant la dégradation du cartilage, la dégradation osseuse et/ou articulaire, par exemple l'ostéoarthrite ; et/ou des états comprenant des réponses inflammatoires ou immunitaires, telles que la maladie de crohn, l'arthrite rhumatoïde, le psoriasis, une maladie allergique des voies respiratoires (par exemple l'asthme, la rhinite), l'arthrite idiopathique juvénile, la rectocolite, les maladies inflammatoires de l'intestin, des états pathologiques induits par l'endotoxine (par exemple des complications après une chirurgie de pontage ou des états chroniques liés à l'endotoxine contribuant par exemple à une insuffisance cardiaque chronique), des maladies comprenant une incapacité de renouvellement du cartilage (par exemple des maladies comprenant la stimulation anabolique de chondrocytes), des malformations congénitales du cartilage, des maladies associées à une hypersécrétion de l'il6 et un rejet de la transplantation (par exemple un rejet d'un organe transplanté) et des maladies prolifératives.
MA33602A 2008-07-25 2011-02-11 Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires MA32551B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13592008P 2008-07-25 2008-07-25
US22068509P 2009-06-26 2009-06-26
PCT/EP2009/059605 WO2010010191A1 (fr) 2008-07-25 2009-07-24 Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires

Publications (1)

Publication Number Publication Date
MA32551B1 true MA32551B1 (fr) 2011-08-01

Family

ID=41021059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33602A MA32551B1 (fr) 2008-07-25 2011-02-11 Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires

Country Status (36)

Country Link
US (5) US8853240B2 (fr)
EP (2) EP2346864B1 (fr)
JP (2) JP5480261B2 (fr)
KR (2) KR101711911B1 (fr)
CN (2) CN102105472B (fr)
AR (1) AR072875A1 (fr)
AU (2) AU2009273144B2 (fr)
BR (2) BRPI0916659B8 (fr)
CA (2) CA2730762C (fr)
CL (1) CL2009001637A1 (fr)
CO (1) CO6361925A2 (fr)
CR (1) CR20110092A (fr)
CY (2) CY1113945T1 (fr)
DK (2) DK2346864T3 (fr)
DO (1) DOP2011000022A (fr)
EA (2) EA018587B1 (fr)
ES (2) ES2485913T3 (fr)
HK (2) HK1158635A1 (fr)
HR (2) HRP20130357T1 (fr)
IL (2) IL210262A (fr)
JO (1) JO3041B1 (fr)
MA (1) MA32551B1 (fr)
ME (1) ME02046B (fr)
MX (2) MX2011000756A (fr)
MY (1) MY157615A (fr)
NZ (1) NZ590646A (fr)
PE (1) PE20100152A1 (fr)
PL (2) PL2361251T3 (fr)
PT (2) PT2346864E (fr)
RS (2) RS52823B (fr)
SI (2) SI2361251T1 (fr)
SM (2) SMT201300051B (fr)
TW (1) TWI447118B (fr)
UY (1) UY32006A (fr)
WO (2) WO2010010191A1 (fr)
ZA (2) ZA201100396B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JP5684245B2 (ja) 2009-06-05 2015-03-11 セファロン、インク． １，２，４−トリアゾロ［１，５ａ］ピリジン誘導体の調製および使用
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20100331222A1 (en) * 2009-06-26 2010-12-30 Basf Se Process for producing cellulose beads from solutions of cellulose in ionic liquid
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2566333A4 (fr) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior Identification de stabilisants de protéines multimériques
WO2012000970A1 (fr) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines en tant qu'inhibiteurs de tyk2
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
EP2951590A1 (fr) 2013-02-04 2015-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes d'analyse de l'activité jak2 dans des globules rouges sanguins et leurs utilisations
EP3010922B1 (fr) * 2013-06-19 2017-03-15 Galapagos NV Nouveaux composés et compositions pharmaceutiques les comprenant pour le traitement de troubles inflammatoires
HUE035264T2 (hu) 2013-12-05 2018-05-02 Pfizer Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
EP3083583B1 (fr) 2013-12-20 2020-11-18 Sagimet Biosciences Inc. Modulateurs hétérocycliques de la synthèse des lipides et combinaisons en contenant
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3179857B1 (fr) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugaison d'agents pharmaceutiquement actifs avec des ligands de transthyrétine par des liants réglables pour augmenter la demi-vie de sérum
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
AU2016212526B2 (en) 2015-01-28 2020-11-05 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd Substituted imidazo (1, 2-a) pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法
HUE044240T2 (hu) * 2015-04-29 2019-10-28 Wuxi Fortune Pharmaceutical Co Ltd Janus kináz (JAK) inhibitorok
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012773A1 (fr) 2015-07-23 2017-01-26 Ratiopharm Gmbh Formes solides de base libre de filgotinib
WO2017012770A1 (fr) 2015-07-23 2017-01-26 Ratiopharm Gmbh Sels d'addition d'acide de filgotinib
WO2017012771A1 (fr) 2015-07-23 2017-01-26 Ratiopharm Gmbh Sels d'addition d'acide sulfonique de filgotinib cristallin
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
WO2017133423A1 (fr) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 Fig. 1 : s102 % % % diviser m ports dmrs en k groupes de ports dmrs, k et m étant des entiers positifs et k étant inférieur ou égal à m s104 % % % utilisent un précodage indépendante sur chaque groupe de ports dmrs pour transmettre dmrs
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
JP6978098B2 (ja) * 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
EA036903B1 (ru) * 2016-10-26 2021-01-13 Янссен Фармацевтика Нв Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора
WO2018080916A1 (fr) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Composés azahétérocycliques fusionnés et leur utilisation en tant que modulateurs des récepteurs ampa
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
IL298196A (en) 2017-02-17 2023-01-01 Eidos Therapeutics Inc Processes for the preparation of ag-10, its intermediates and salts
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2018167283A1 (fr) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US11427581B2 (en) 2018-01-31 2022-08-30 Zhuhai United Laboratories Co., Ltd. JAK inhibitor and use thereof
CA3091142C (fr) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Composes de pyrrolizine substitues et utilisations connexes
EP3758700B1 (fr) 2018-02-28 2024-07-31 University of Southern California Compositions pour la modulation de maladies inflammatoires et dégénératives
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
TWI834708B (zh) 2018-08-17 2024-03-11 美商文涵治療有限公司 Ag10之調配物
CA3106490C (fr) 2018-08-23 2023-03-07 Zhuhai United Laboratories Co., Ltd. Compose [1,2,4]triazolo[1,5-a]pyridine utilise en tant qu'inhibiteur de jak et son utilisation
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
WO2020097400A1 (fr) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
MX2021015996A (es) 2019-07-11 2022-06-08 Escape Bio Inc Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).
US20220274983A1 (en) * 2019-08-06 2022-09-01 Jiangsu Carephar Pharmaceutical Co., Ltd. Jak kinase inhibitor and use thereof
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
EP4105214A4 (fr) * 2020-02-13 2023-11-08 Zhuhai United Laboratories Co., Ltd. Utilisation d'inhibiteurs de kinase jak dans la préparation de médicaments pour traiter des maladies associées à la kinase jak
JP7530432B2 (ja) * 2020-02-21 2024-08-07 チューハイ ユナイテッド ラボラトリーズ カンパニー リミテッド Ｊａｋ阻害剤の結晶形およびその使用
CN115996917A (zh) 2020-05-06 2023-04-21 艾捷斯治疗公司 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
CN111617318B (zh) * 2020-05-26 2021-12-10 南京市儿童医院 可注射型儿童骺板再生水凝胶的制备方法
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN114394965B (zh) * 2021-01-29 2023-09-12 深圳市乐土生物医药有限公司 三唑并吡啶类化合物及其制备方法与用途
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60016384T2 (de) * 1999-01-29 2005-12-01 Chugai Seiyaku K.K. Chondrogonese promotoren und indolin-2-on derivate
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
MXPA05008568A (es) 2003-02-14 2005-11-04 Pfizer Prod Inc Nuevos compuestos anti-inflamatorios triazolo-piridinas.
TWI221602B (en) * 2003-07-21 2004-10-01 Benq Corp Emergent disc-withdrawing apparatus
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
CA2582482A1 (fr) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Agents antibacteriens
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CN103641829A (zh) * 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
US7977352B2 (en) * 2006-12-01 2011-07-12 Galapagos Nv Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
PE20090370A1 (es) * 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
JP2010533680A (ja) * 2007-07-18 2010-10-28 ノバルティス アーゲー 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用
WO2009017954A1 (fr) 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
AU2008291075A1 (en) * 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8284682B2 (en) * 2008-02-19 2012-10-09 Qualcomm, Incorporated Facilitating transfer of push and pull messages for remotely testing mobile devices
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010186A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
DE102009000543A1 (de) * 2009-02-02 2010-08-12 Evonik Degussa Gmbh Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen
CA2750460C (fr) * 2009-02-02 2017-01-24 Basf Se Absorbant contenant des amines cycliques pour eliminer des gaz acides
JP5684245B2 (ja) 2009-06-05 2015-03-11 セファロン、インク． １，２，４−トリアゾロ［１，５ａ］ピリジン誘導体の調製および使用
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
SI2863950T1 (sl) 2012-06-22 2018-10-30 Galapagos Nv Aminotriazolopiridin za uporabo pri zdravljenju vnetja in njegovi farmacevtski sestavki

Also Published As

Publication number Publication date
BRPI0916862B8 (pt) 2021-05-25
US20170035738A1 (en) 2017-02-09
HK1158634A1 (en) 2012-07-20
CR20110092A (es) 2011-03-16
JP5480261B2 (ja) 2014-04-23
TWI447118B (zh) 2014-08-01
EA201170255A1 (ru) 2011-08-30
RS52823B (en) 2013-10-31
RS53406B (en) 2014-10-31
MX2011000756A (es) 2011-03-21
EP2346864B1 (fr) 2013-03-06
ES2406691T3 (es) 2013-06-07
KR101676391B1 (ko) 2016-11-15
AR072875A1 (es) 2010-09-29
ZA201100396B (en) 2011-10-26
SMT201400072B (it) 2014-09-08
AU2009273143B2 (en) 2014-01-23
US8853240B2 (en) 2014-10-07
WO2010010190A1 (fr) 2010-01-28
AU2009273144B2 (en) 2013-10-31
ES2485913T3 (es) 2014-08-14
MX2011000758A (es) 2011-02-23
IL210261A (en) 2017-03-30
EP2361251B1 (fr) 2014-04-30
AU2009273143A1 (en) 2010-01-28
US20110190260A1 (en) 2011-08-04
SMT201300051B (it) 2013-07-09
KR20110053435A (ko) 2011-05-23
CL2009001637A1 (es) 2010-02-19
PL2346864T3 (pl) 2013-08-30
BRPI0916862A2 (pt) 2016-02-10
PE20100152A1 (es) 2010-03-24
KR101711911B1 (ko) 2017-03-03
CA2730762C (fr) 2017-11-21
SI2346864T1 (sl) 2013-05-31
IL210262A0 (en) 2011-03-31
CN102105472B (zh) 2013-04-17
KR20110045020A (ko) 2011-05-03
BRPI0916659B1 (pt) 2020-12-08
JP2011529032A (ja) 2011-12-01
US8242274B2 (en) 2012-08-14
EP2346864A1 (fr) 2011-07-27
EP2361251A1 (fr) 2011-08-31
CA2730757A1 (fr) 2010-01-28
AU2009273144A1 (en) 2010-01-28
CY1113945T1 (el) 2016-07-27
CN102105471B (zh) 2014-10-15
CN102105471A (zh) 2011-06-22
JP2011529033A (ja) 2011-12-01
CN102105472A (zh) 2011-06-22
ME02046B (me) 2015-05-20
DOP2011000022A (es) 2011-03-31
EA018587B1 (ru) 2013-09-30
CO6361925A2 (es) 2012-01-20
WO2010010191A1 (fr) 2010-01-28
US9415037B2 (en) 2016-08-16
CY1115569T1 (el) 2017-01-04
PL2361251T3 (pl) 2014-10-31
HRP20130357T1 (en) 2013-05-31
IL210262A (en) 2014-09-30
US20100029709A1 (en) 2010-02-04
SI2361251T1 (sl) 2014-09-30
BRPI0916659A2 (pt) 2019-03-12
BRPI0916659B8 (pt) 2021-05-25
PT2346864E (pt) 2013-04-04
EA018080B1 (ru) 2013-05-30
HRP20140681T1 (hr) 2014-10-24
PT2361251E (pt) 2014-07-11
MY157615A (en) 2016-06-30
EA201170257A1 (ru) 2011-08-30
HK1158635A1 (en) 2012-07-20
IL210261A0 (en) 2011-03-31
CA2730762A1 (fr) 2010-01-28
TW201008939A (en) 2010-03-01
US20120309784A1 (en) 2012-12-06
US20150150856A1 (en) 2015-06-04
UY32006A (es) 2010-02-26
ZA201100472B (en) 2011-10-26
JP5559168B2 (ja) 2014-07-23
DK2346864T3 (da) 2013-05-13
US10206907B2 (en) 2019-02-19
DK2361251T3 (da) 2014-07-21
NZ590646A (en) 2011-11-25
BRPI0916862B1 (pt) 2020-08-11
JO3041B1 (ar) 2016-09-05

Similar Documents

Publication Publication Date Title
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
CR20130045A (es) Compuestos terapéuticos
MA32938B1 (fr) Composes organiques
UA110338C2 (en) Chemical compounds
SMT201400169B (it) Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie
EA200900945A1 (ru) Новый способ синтеза агомелатина
CR20120295A (es) Triazolopiridinas
MA32487B1 (fr) Nouvelles pyridine-2-ones et pyridazine-3-ones substituees
HK1195311A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
EA201170832A1 (ru) Пуриновые соединения
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EA200900946A1 (ru) Новый способ синтеза агомелатина
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA201291235A1 (ru) Новые способы
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
DK2144607T3 (da) Sammensætninger til bidrag til behandlingen af cancer